U.S. Obesity Treatment Market Size & Outlook, 2024-2030
U.S. obesity treatment market, 2018-2030 (US$M)
Related Markets
U.S. obesity treatment market highlights
- The U.S. obesity treatment market generated a revenue of USD 11,194.0 million in 2024 and is expected to reach USD 48,498.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 24.2% from 2025 to 2030.
- In terms of segment, glp-1 receptor agonists was the largest revenue generating drug class in 2024.
- Other Drug Class is the most lucrative drug class segment registering the fastest growth during the forecast period.
Obesity treatment market data book summary
| Market revenue in 2024 | USD 11,194.0 million |
| Market revenue in 2030 | USD 48,498.2 million |
| Growth rate | 24.2% (CAGR from 2025 to 2030) |
| Largest segment | Glp-1 receptor agonists |
| Fastest growing segment | Other Drug Class |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | GLP-1 Receptor Agonists, Lipase Inhibitors (Orlistat), Appetite Suppressants (Phentermine, Lorcaserin), Other Drug Class |
Other key industry trends
- In terms of revenue, U.S. accounted for 70.3% of the global obesity treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. obesity treatment market is projected to lead the regional market in terms of revenue in 2030.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 48,498.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Obesity Treatment Market Scope
Obesity Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. obesity treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to obesity treatment market will help companies and investors design strategic landscapes.
Glp-1 receptor agonists was the largest segment with a revenue share of 135.64% in 2024. Horizon Databook has segmented the U.S. obesity treatment market based on glp-1 receptor agonists, lipase inhibitors (orlistat), appetite suppressants (phentermine, lorcaserin), other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to U.S. obesity treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. obesity treatment market databook
-
Our clientele includes a mix of obesity treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. obesity treatment market , including forecasts for subscribers. This country databook contains high-level insights into U.S. obesity treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
US Drug Class - Obesity Treatment Market size, 2024 - 2030 (US$M)
U.S. Obesity Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
